Analyzing Intensity Therapeutics (NASDAQ:INTS) and Tribute Pharmaceuticals Canada (OTCMKTS:TBUFF)

Tribute Pharmaceuticals Canada (OTCMKTS:TBUFF) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Insider & Institutional Ownership

3.7% of Intensity Therapeutics shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Tribute Pharmaceuticals Canada and Intensity Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tribute Pharmaceuticals Canada	N/A	N/A	N/A	N/A	N/A
Intensity Therapeutics	N/A	N/A	-$11.61 million	($3.57)	-1.18

Profitability

This table compares Tribute Pharmaceuticals Canada and Intensity Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tribute Pharmaceuticals Canada	N/A	N/A	N/A
Intensity Therapeutics	N/A	-116.61%	-94.01%

Analyst Ratings

This is a summary of current ratings and price targets for Tribute Pharmaceuticals Canada and Intensity Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tribute Pharmaceuticals Canada	0	0	0	0	0.00
Intensity Therapeutics	1	0	3	1	2.80

Intensity Therapeutics has a consensus target price of $22.25, suggesting a potential upside of 429.76%. Given Intensity Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Intensity Therapeutics is more favorable than Tribute Pharmaceuticals Canada.

Summary

Intensity Therapeutics beats Tribute Pharmaceuticals Canada on 6 of the 8 factors compared between the two stocks.

About Tribute Pharmaceuticals Canada

Tribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.

About Intensity Therapeutics

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.